In this article, we will discuss the 5 Best Rated Penny Stocks to Buy According to Wall Street Analysts. For deeper discussion and analysis, read 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts.

5. Alight, Inc. (NYSE:ALIT)

Upside Potential: 58.75%

On May 13, Alight, Inc. (NYSE:ALIT) announced the expansion of its Alight Partner Network through the addition of Cylinder Health and Leap. The company stated that the additions strengthen Alight’s ability to help employers deliver high-impact health and employee engagement solutions through an integrated ecosystem of workplace services. The Alight Partner Network is designed to provide employers with curated healthcare, benefits, and wellness offerings that improve employee engagement and streamline access to specialized solutions through existing Alight client relationships. Management believes the expanded network will enhance the company’s ability to provide more connected and personalized employee experiences.

Earlier, on May 1, Alight, Inc. (NYSE:ALIT) announced two executive leadership appointments aimed at supporting operational execution and long-term growth initiatives. Dinesh Tulsiani was appointed President of Employer Solutions effective May 1, 2026, while Susan Davies, previously the company’s Chief Accounting Officer and Global Controller, was named Interim Chief Financial Officer effective May 8, 2026, following the previously announced departure of Greg Giometti. The leadership changes reflect Alight’s continued emphasis on operational excellence, innovation, and strategic expansion across its cloud-based HR and employee benefits platform.

Founded in 2017 and headquartered in Chicago, Alight, Inc. (NYSE:ALIT) is a cloud-based provider of human resources, payroll, employee engagement, and financial wellness technology solutions for large organizations.

4. Prairie Operating Co. (NASDAQ:PROP)

Upside Potential: 329.07%

On May 15, Roth Capital lowered its price target on Prairie Operating Co. (NASDAQ:PROP) to $3.50 from $4 while maintaining a Buy rating following the company’s first-quarter report. The firm reduced its 2026 cash flow per share estimates by approximately 20%, citing weaker first-quarter performance, an increased share count, and hedge positions that were below the firm’s commodity price assumptions. Despite the downward revision, Roth Capital maintained a constructive view on the shares, suggesting that the company still offers attractive long-term upside potential relative to current valuation levels.

Previously, on April 10, Roth Capital analyst Leo Mariani characterized the sharp selloff in Prairie Operating Co. (NASDAQ:PROP) shares following the restructuring of its preferred stock agreement as a buying opportunity. The company reached an agreement with preferred shareholder Hudson Bay to reduce anniversary warrant coverage from 125% to 75% of stated value, lowering potential dilution from approximately 77 million shares to 34 million shares while extending the warrant issuance deadline to July 8, 2026. In exchange, Hudson Bay received immediate penny warrants covering 4 million shares, with an additional 3 million-share warrant contingent upon future issuance conditions. Although Roth reduced earnings estimates due to the higher share count, the firm expressed surprise at the severity of the market reaction and reiterated its Buy rating.

Founded in 2023 and headquartered in Houston, Prairie Operating Co. (NASDAQ:PROP) is an independent energy company focused on the acquisition, development, and production of crude oil, natural gas, and natural gas liquids. Its core operations are concentrated within the Denver-Julesburg Basin in Weld County, Colorado.

3. Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Upside Potential: 843.40%

On May 18, H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) with a Buy rating and a $4 price target. According to the analyst, the company’s lead therapy, LYMPHIR, has already received approval for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma. H.C. Wainwright noted that early commercial launch metrics appear encouraging, highlighting nearly full commercial insurance coverage, strong formulary positioning across target healthcare accounts, and the company’s initial international shipment into Europe through a regional distribution partner. The firm believes these developments support the broader commercialization outlook for LYMPHIR as Citius continues expanding market access.

Previously, on April 29, Citius Oncology, the majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), announced the first shipment of LYMPHIR into Europe through one of its regional distribution partners. The therapy will initially be provided to eligible patients through Named Patient Programs in accordance with local country regulations. Management described the European launch initiative as an important strategic milestone in expanding international access for patients with limited treatment options while maintaining a disciplined commercial rollout strategy. LYMPHIR previously received approval from the U.S. Food and Drug Administration in August 2024 for adult patients with relapsed or refractory cutaneous T-cell lymphoma following at least one prior systemic therapy and was commercially launched in the United States in December 2025.

Founded in 2007 and headquartered in Cranford, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a late-stage biopharmaceutical company focused on developing and commercializing critical care and oncology therapies. The company’s pipeline includes treatments targeting unmet medical needs in oncology, infectious disease management, and supportive care markets.

2. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

Upside Potential: 1194.87%

On May 13, Lucid Capital initiated coverage of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) with a Buy rating and a $49 price target. The firm stated that NRx is preparing to enter the approximately $1.5 billion North American ketamine market through both a proprietary generic product and a branded formulation. According to the analyst, the company has developed a preservative-free ketamine formulation with a potential shelf life of up to three years, which could represent a meaningful competitive advantage within the market. Lucid Capital believes the company’s differentiated formulation and manufacturing capabilities position it favorably as demand grows for mental health and central nervous system therapies.

Earlier, on May 5, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced the initiation of its first commercial manufacturing order for its preservative-free ketamine product ahead of an anticipated approval expected during the summer of 2026. Chairman and Chief Executive Officer Jonathan Javitt stated that the company looks forward to delivering a safe and convenient U.S.-manufactured ketamine product to the market. Management noted that the manufacturing order follows stability data from multiple registration batches and a successful third-party audit of the manufacturing facility. The company also emphasized that its blow-fill-seal manufacturing process enables production throughput more than ten times greater than traditional sterile bottling methods while supporting rapid future scalability as demand increases.

Founded in 2015 and headquartered in Wilmington, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies targeting central nervous system disorders, including severe suicidal depression, post-traumatic stress disorder, and bipolar depression.

1. VolitionRx Limited (NYSEAMERICAN:VNRX)

Upside Potential: 1451.32%

On May 15, Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx Limited (NYSEAMERICAN:VNRX), stated that the company made substantial progress across multiple product platforms during the first quarter and following quarter-end developments. Management highlighted the submission for peer review of a clinical manuscript demonstrating high accuracy for the company’s Nu.Q Vet feline prototype assay in detecting lymphoma in cats, representing the third animal species supported by the platform. VolitionRx noted that publication of the study in a peer-reviewed journal is expected to trigger a $5 million contractual milestone payment. The company also believes the feline assay could significantly expand the commercial opportunity for its Nu.Q Vet diagnostic platform within veterinary healthcare markets.

Previously, on April 29, VolitionRx Limited (NYSEAMERICAN:VNRX) announced a major technical milestone involving the successful detection of nucleosomes in capillary blood samples collected from critically ill sepsis patients using the company’s lateral flow prototype technology. The finger-prick testing platform is designed for potential bedside, emergency room, or at-home diagnostic use, similar to rapid COVID-19 or pregnancy tests. Management stated that the study, conducted as part of the SUMMIT program, demonstrated the feasibility of rapidly detecting immune disruptions associated with conditions such as sepsis without requiring centralized laboratory analysis. The advancement could substantially broaden the market opportunity for VolitionRx’s diagnostic technologies beyond traditional clinical laboratory settings.

Founded in 1998 and headquartered in Henderson, VolitionRx Limited (NYSEAMERICAN:VNRX) is a multinational epigenetics company focused on developing cost-effective blood tests for early cancer detection and immune monitoring in both humans and animals. The company’s proprietary technologies analyze nucleosomes circulating in the bloodstream to help identify and monitor serious diseases and health conditions.

READ NEXT: 7 Best Heavy Equipment Stocks to Buy as Backlogs Hit Records and 8 Best Rising Tech Stocks to Buy According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.